Ventyx Biosciences, Inc. (VTYX)

US — Healthcare Sector
Peers: NUVL  ACLX  PCVX  VRDN  DAWN  AMLX 

Automate Your Wheel Strategy on VTYX

With Tiblio's Option Bot, you can configure your own wheel strategy including VTYX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol VTYX
  • Rev/Share 0.0
  • Book/Share 3.2564
  • PB 0.8721
  • Debt/Equity 0.0455
  • CurrentRatio 19.5706
  • ROIC -0.5648

 

  • MktCap 202097808.0
  • FreeCF/Share -1.533
  • PFCF -1.8533
  • PE -1.6293
  • Debt/Assets 0.0416
  • DivYield 0
  • ROE -0.4745

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 5
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock?
VTYX
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive

Ventyx Biosciences (VTYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Read More
image for news Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock?
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025
VTYX
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral

Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markers Full analysis of Phase 2 results, including data from the 52-week treat-through LTE phase, is expected to inform development strategy and partnership opportunities for VTX958 SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that data from the Phase 2 trial of its TYK2 inhibitor VTX958 in Crohn's disease will be presented during the 20th Congress of the European Crohn's …

Read More
image for news Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025

About Ventyx Biosciences, Inc. (VTYX)

  • IPO Date 2021-10-21
  • Website https://www.ventyxbio.com
  • Industry Biotechnology
  • CEO Raju S. Mohan
  • Employees 81
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.